Carisma Therapeutics, Inc. stock is down -4.91% since 30 days ago. The next earnings date is Feb 25, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 9 December’s closed higher than November. 100% of analysts rate it a buy.
Carisma Therapeutics Inc. a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) Its lead product candidates include Vicineum, which is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer. The company was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.